Epigenetic Deficiencies and Replicative Stress: Driving Cancer Cells to an Early Grave

Area of Science:

• Oncology
• Cancer Biology
• Epigenetics

Background:

• Synthetic lethal interactions represent a promising strategy for targeted cancer therapy.
• Identifying novel synthetic lethal partners is crucial for developing effective cancer treatments.
• SETD2 mutations and subsequent loss of H3K36 trimethylation are observed in various cancers.

Purpose of the Study:

• To investigate a novel synthetic lethal interaction involving histone modification in cancer cells.
• To explore the therapeutic potential of targeting WEE1 kinase in cancers with SETD2 loss-of-function mutations.

Main Methods:

• Utilized genetic screening and cell-based assays to identify synthetic lethal interactions.
• Assessed the sensitivity of cancer cells with SETD2 mutations to WEE1 inhibition.
• Analyzed the role of H3K36 trimethylation in mediating this sensitivity.

Main Results:

• Discovered a synthetic lethal interaction between loss of SETD2 function (and H3K36 trimethylation) and WEE1 inhibition.
• Cancer cells with SETD2 loss-of-function mutations showed significant sensitization to WEE1 inhibitors.
• This sensitization was linked to the absence of H3K36 trimethylation.

Conclusions:

• Targeting WEE1 kinase is a viable therapeutic strategy for cancers harboring SETD2 loss-of-function mutations.
• The synthetic lethal interaction between SETD2 deficiency and WEE1 inhibition offers a new avenue for cancer treatment.
• Epigenetic alterations, such as loss of H3K36 trimethylation, can be exploited for targeted cancer therapies.